NCT02351037 2018-08-14Study of Ibrutinib in Subjects With Acute Myeloid LeukemiaPharmacyclics LLC.Phase 2 Terminated36 enrolled 12 charts
NCT02635074 2018-05-14Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaStanford UniversityPhase 1 Terminated2 enrolled